Aytu BioPharma, Inc. (NASDAQ:AYTU) Short Interest Update

Aytu BioPharma, Inc. (NASDAQ:AYTU) was the target of a significant drop in short interest in the month of November. As of November 15th, there was short interest totalling 120,800 shares, a drop of 37.3% from the October 31st total of 192,800 shares. Approximately 2.0% of the shares of the stock are short sold. Based on an average trading volume of 29,500 shares, the days-to-cover ratio is currently 4.1 days.

Aytu BioPharma Price Performance

Shares of AYTU stock traded down $0.01 during mid-day trading on Friday, hitting $1.61. 18,152 shares of the stock traded hands, compared to its average volume of 22,925. Aytu BioPharma has a twelve month low of $1.41 and a twelve month high of $3.45. The company has a debt-to-equity ratio of 0.35, a quick ratio of 0.80 and a current ratio of 0.99. The company’s 50-day simple moving average is $2.02 and its 200-day simple moving average is $2.50. The firm has a market cap of $9.90 million, a price-to-earnings ratio of -1.31 and a beta of -1.40.

Aytu BioPharma (NASDAQ:AYTU) last issued its quarterly earnings results on Thursday, September 26th. The company reported ($0.82) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.37). Aytu BioPharma had a negative return on equity of 21.89% and a negative net margin of 8.28%. The business had revenue of $17.98 million during the quarter.

Institutional Trading of Aytu BioPharma

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Dimensional Fund Advisors LP grew its position in Aytu BioPharma by 54.5% in the second quarter. Dimensional Fund Advisors LP now owns 23,551 shares of the company’s stock worth $69,000 after buying an additional 8,311 shares during the last quarter. Armistice Capital LLC acquired a new stake in shares of Aytu BioPharma during the 2nd quarter valued at $736,000. Finally, Stonepine Capital Management LLC boosted its stake in shares of Aytu BioPharma by 6.0% during the 3rd quarter. Stonepine Capital Management LLC now owns 500,958 shares of the company’s stock worth $1,177,000 after acquiring an additional 28,489 shares in the last quarter. 33.49% of the stock is currently owned by institutional investors.

Aytu BioPharma Company Profile

Aytu Biopharma, Inc, a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates through two segments: Rx segment and Consumer Health segment. The Rx segment offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years and older, and Cotempla XR-ODT for patients from six to seventeen years old.